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The American Cancer Society estimates that approximately 480,000 adults are diagnosed annually with melanomas or reproductive or gastrointestinal cancers, for which treatments include irradiation and/or removal of lymph nodes from the groin or the abdomen. 1 A common concern for these survivors of cancer is lymphedema of the legs and the feet, known as lower limb lymphedema (LLL). LLL is an abnormal accumulation of proteinrich fluid in the affected limb, which can occur after lymph node removal, trauma, or irradiation. 2, 3 This chronic progressive condition has no known cure and has negative effects on wound healing, local blood flow, tissue oxygenation, 4Y6 as well as physical function and quality-of-life. 7Y9 The prevalence of LLL widely varies, depending on diagnostic criteria, intensity of lymph node treatment, and length of follow-up. Estimates suggest that 20%Y30% of those who underwent lymph node removal, trauma, or irradiation to the groin or the abdomen may develop LLL. 10 Despite the large proportion of survivors of cancer with or at risk for LLL (È140,000 survivors of cancer per year), scant research has examined symptoms in the legs and the feet reported by survivors of cancer with or at risk for LLL. 3, 11 This gap in evidence constrains the ability of clinicians to counsel their patients regarding the symptoms and physical impairments that may be developed after surgery or radiation therapy.
To this end, the authors conducted a crosssectional survey of survivors of cancer diagnosed in the previous 3Y5 yrs whose diagnoses and treatment placed them at increased risk of developing LLL. The authors inquired about common symptoms experienced in the legs and the feet since completing cancer treatment.
METHODS

Population
In the spring of 2009, the Pennsylvania Cancer Registry was used to identify a random populationbased sample of potentially eligible participants living in three Pennsylvania counties (Philadelphia, Montgomery, or Delaware) and in zip codes within 10 miles of the University of Pennsylvania. All potential participants were diagnosed with stage IIYIII cancer between 2004 and 2006 that included melanoma and uterine, ovarian, cervical, endometrial, bladder, penile, testicular, and colorectal cancers that might have included removal of lymph nodes or radiation of the abdomen or the groin. 1 The National Death Index was used to confirm that the potentially eligible survivors of cancer identified through the Pennsylvania Cancer Registry were alive at the time of the mailing. The University of Pennsylvania's Institutional Review Board policies and approvals were rigorously adhered to throughout this research study. The participants provided informed consent by returning the completed survey and completed the written informed consent before the in-person clinical assessment.
Mailed Survey
In the summer of 2009, letters were mailed to 202 survivors of cancer with a brochure that explained the Pennsylvania Cancer Registry (available at the registry Website) and a cover letter informing that they would receive a mailed questionnaire asking about the symptoms in their lower limbs. The authors asked the eligible participants to inform them if they were not interested in participating in the study and receiving subsequent mailings. Two weeks later, a questionnaire was mailed to all survivors of cancer who did not decline participation. This second letter included a cover letter explaining the purpose of the study, the study survey, a postage-paid self-addressed return envelope, and $1 attached to thank participants for their time. Four weeks later, a third letter was mailed to the participants who did not reply to the second mailing. No monetary remuneration was included in the third mailing.
The mailed survey asked questions about demographic characteristics (race, education, and occupation), cancer treatment history (type of cancer, treatment received, and history of lymphedema), and previous knowledge about LLL. The authors also asked about leg and foot symptoms that started after cancer treatment. Eighteen specific leg and foot symptoms related to LLL were asked. This questionnaire was based on the Norman Lymphedema Survey, 12 a valid and reliable survey for diagnosing breast cancerYrelated lymphedema (Table 1 ; see supplemental digital content for specific symptoms). The symptoms were revised to match those thought to be common with LLL in consultation with the lead therapist for the Lymphedema Service at the University of Pennsylvania (more than 20 yrs of clinical experience with lymphedema).
Clinic Visit
The authors invited all participants who returned the mailed survey for a 30-min in-person physical therapy examination at Penn Therapy and Fitness (located in Philadelphia, PA). This 30-min examination included circumference measurement of the legs and a standard physical therapy clinical examination of skin tissue tone and texture and clinical history taking of leg symptoms. The patients were also asked whether they had any vascular disease diagnoses to delineate those for whom symptoms could be caused by conditions other than lymphedema. Those who completed this in-person clinical assessment were remunerated $20 and were asked whether it was likely that their symptoms were consistent with a diagnosis of LLL in accordance with the Common Toxicity Criteria grading (Common Toxicity Criteria for Adverse Events Version 3.0). 13 If a participant seemed to have lymphedema, according to this study's inperson screening, they were referred for appropriate treatment and follow-up care. 10 
Statistical Analysis
The authors calculated the percentages for the response rate for the letters mailed using the methods described by the American Association for 
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Public Opinion Research. 14 They compared demographic and clinical characteristics and number of leg and foot symptoms between the participants who had the in-person clinical examination vs. those who did not. Categorical variables are presented using rates (percent) and were compared between the groups using Fisher's exact test. Continuous variables are presented using means T standard deviation or median and interquartile range and were compared between the groups using Wilcoxon's rank-sum test. Statistical significance was established at P G 0.05. All statistical analyses were conducted using Stata 12.0 (College Station, TX).
RESULTS
Mailed Survey Results
The authors mailed 202 informational letters to eligible survivors of cancer. Three potentially eligible participants were not interested in participating in the study survey. The authors mailed 199 and 75 surveys in the first and second cycles of mailing. The response rate to the mailed surveys was 57.2% (Fig. 1 ). The authors received 97 completed surveys and 10 partially completed surveys to contribute to the subsequent data analysis (107 surveys in total). The level of education varied among the participants, and the majority reported being retired (Table 2) . Among the 107 participants, 78% reported being unsure or never hearing about lymphedema (Table 3 ). Eighteen percent did not know whether they had lymph nodes removed for their cancer treatment.
The next section of the study survey inquired about the symptoms experienced in the lower limbs. The number of self-reported symptoms ranged from 0 to 18 and was highly skewed (Fig. 2) . Among those with a previous diagnosis of LLL, the median number of self-reported symptoms was 2 (interquartile range, 0Y10). The median number of selfreported symptoms did not statistically differ between those with vs. those without a previous diagnosis of LLL (P = 0.21). Among the 107 survivors of cancer who answered the study survey, 37 (34.5%) reported one or more symptoms. The most common symptoms associated with LLL were difficulty walking (n = 37; 100%), aching (n = 32; 86%), puffiness (n = 28; 76%), and pain (n = 27; 73%) on one side of the body since cancer treatment ( Fig. 3 ). Among the 37 survivors of cancer experiencing symptoms associated with LLL, 30 (81%) had three or more symptoms. Among the 30 participants reporting three or more symptoms, 18 (60%) were 65 yrs or older (P = 0.05).
In-Person Clinical Assessment
The authors invited all 107 participants who completed all or part of the mailed survey to have an in-person clinical assessment, and 17 (16%) attended. Those who came to the clinic were younger and had a professional occupation ( Table 2) . Those who came to the clinic were more likely to have a previous diagnosis of LLL and to report more symptoms associated with LLL (Table 3 ). In accordance with the Common Toxicity Criteria version 3.0, among the 17 participants who underwent the in-person clinical assessment, 10 participants showed no evidence of LLL and five and two participants showed evidence of grade 1 and 2 lymphedema, respectively. 13 The authors identified three patients with previously undiagnosed LLL aged 63, 70, and 71 yrs old with 9, 5, and 18 self-reported symptoms, respectively (Fig. 4) . The in-person clinical assessment identified ten participants with no evidence of LLL, yet these participants reported an average of 5.5 symptoms in their lower limbs 
DISCUSSION
The major finding of this study is that 78% of the survivors of cancer surveyed reported being unsure or never hearing about LLL. In addition, 35% of the survivors of long-term cancer in this study's sample reported one or more symptoms in their legs or feet for which onset occurred after completing cancer treatment. Among the 37 participants who reported symptoms, 30 (81%) reported three or more symptoms. Among the six participants who reported a previous diagnosis of LLL, three (50%) reported 3 or more symptoms, with 4, 10, and 16 self-reported symptoms. The most common symptoms reported were difficulty walking, aching, puffiness, and pain. Using in-person clinical assessments among a self-selected subsample of 17 participants, three cases of previously undiagnosed LLL were identified. In a previous report among 231 survivors of gynecologic cancer surveyed 3 mos to 5 yrs after diagnosis, 25% stated that they would want to be more informed about the causes, prevention, and treatment of LLL. 11 Twenty-five percent also indicated that they would like written information about ways to manage symptoms of LLL, 19% indicated that they would like assistance in managing the symptoms associated with LLL, and 12% indicated needing help in managing the symptoms of LLL at work and in completing activities of daily living at home. In this study's sample, among those who attended the in-person clinical assessment, 100% said they would be interested in participating in a physical rehabilitation program if such a resource becomes available in the future.
Substantiating the self-reported functional impairments reported in this study's sample, a small pilot study (n = 10) of survivors of cancer with LLL observed 6-min walk distance and single-leg stands, which were 30% and 12% lower than agematched normative values, respectively. 9 However, during this pilot study, two (20%) of the ten participants were diagnosed with cellulitis, a bacterial infection requiring broad-spectrum antibiotics and cessation of exercise. It is unknown whether the two reported cases of cellulitis were directly related to exercise training and the environment in which the exercise training was performed or unrelated to exercise entirely. Therefore, the risk-benefit ratio of exercise or physical activity remains to be elucidated. Conversely, among survivors of breast cancer with upper limb lymphedema, weight-lifting exercise is known to be safe and is known to reduce lymphedema exacerbations and lymphedema symptom severity. 15 It is plausible that survivors of cancer who engage in more physical activity report fewer, less intense, more transient symptoms and side effects associated with LLL. Research is needed to establish the safety, feasibility, and efficacy of prevention and treatment rehabilitation interventions for survivors of cancer with lower extremity symptoms, including those with LLL.
Despite common assumptions, numerous differences exist between LLL and upper limb lymphedema reported by survivors of breast cancer. Anatomic and hemodynamic differences exist, such that the lower limbs need to move a larger volume of lymphatic fluid for a longer distance compared with the arm. 16 Previous reports among upper limb lymphedema suggest avoiding use of the affected limb 17 ; this recommendation has been questioned given the emerging evidence of the safety of upper body weight lifting among survivors of breast cancer with or at risk for upper limb lymphedema. 15, 18 Nonetheless, avoiding the use of the affected arm (i.e., carrying groceries) may be easier than avoiding the use of the lower limb (i.e., walking). Further, LLL may be confused with lower limb venous disease, making diagnosis and treatment more complex than with upper limb lymphedema. 18 These anatomic, physiologic, and functional differences between LLL and upper limb lymphedema provide a rationale for establishing a foundation of evidence that provides as much depth and breadth as seen in upper limb lymphedema, 19Y22 with the goal of providing evidence-based clinical recommendations and interventions among those with or at risk for LLL.
Survivors of cancer are living longer after diagnosis of cancer because of improved surgical, chemotherapeutic, and radiation techniques. The increasing number of survivors of cancer living 5 yrs or longer after diagnosis has provided numerous challenges to the cancer survivors as they attempt to reap high qualities-of-life while traversing the immediate and late side effects that result from cancer treatment. 23 For example, the mean number of lymph nodes removed among those with uterine corpus malignancies at a large metropolitan cancer center 3 increased from 4 in 1994 to 18 in 2003. This 350% increase in removal of lymph nodes provides the capacity for better treatment through increased pathologic evidence for diagnostic tumor staging of cancer. However, this increase was associated with an increased rate of LLL (G1% in 1994 compared with 6% in 2003). The percentage of patients with ten or more lymph nodes removed at this metropolitan cancer center 3 increased from 8% in 1993 to 70% in 2003. Surgical removal of lymph nodes is an established risk factor for LLL, increasing the risk by 2-to 3-fold among gynecologic cancers in a dose-response fashion with the number of lymph nodes removed. 2, 11 Therefore, patients undergoing surgery and lymph node removal need education about the signs and symptoms of LLL, the likelihood of experiencing these signs and symptoms, and knowledge of interventions to manage these signs and symptoms, once identified. To date, few such interventions exist. 9,10 A 20-item questionnaire designed to identify cases of LLL was recently published. 24 The questionnaire is self-administered and takes less than 10 mins to complete. Providing a questionnaire at routine follow-up appointments to survivors of cancer who are at risk for developing LLL may aid to identify symptoms to diagnose and treat LLL in a timely manner.
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Risk reduction practices to minimize the risk of LLL onset or flare-up are similar to those with upper limb lymphedema, 10,21 despite the discussed anatomic, physiologic, and functional differences above. 16 These practices include avoiding constriction, infection, and inflammation; increasing lymphatic circulation; and using caution during air travel. LLL may occur months or years after surgery; therefore, these risk-reduction practices should become habitual to reduce the risk of eliciting an onset of LLL. The authors remind readers that swollen lower limbs are not exclusively indicative of LLL. Swollen lower limbs may suggest deep vein thrombosis or congestive heart failure particularly among older survivors of cancer with existing comorbid conditions. 16 Therefore, all patients should be encouraged to call their healthcare provider if they experience any change in LLL symptoms. This study's sample reported numerous symptoms in the lower limbs since completing cancer treatment. Furthermore, among the 17 participants who underwent an in-person clinical examination, 3 (18%) patients with previously undiagnosed LLL were identified. This is consistent with a previous report that identified 14% of survivors of gynecologic cancer with undiagnosed lower limb swelling. 11 This evidence is consistent with the hypothesis of an existing gap in communication between patients and healthcare providers, which is likely caused by the insufficient foundation of evidence tailored to LLL.
The major limitation of this study is that the most prevalent symptoms identified in the study survey, aching, difficulty walking, pain, puffiness, and weakness, are more frequently caused by exceedingly common (especially among older patients) nonlymphedema conditions, such as osteoarthritis, and diabetic neuropathy, which limits the authors' knowledge of LLL-specific symptoms. This may provide one explanation as to why the participants who attended the in-person clinical assessment who did not have evidence of LLL reported an average of 5.5 symptoms in the lower limbs. The survey did not inquire about comorbidities that are associated with the most prevalent symptoms; therefore, the authors cannot conclude whether these symptoms are indicative of LLL or other nonlymphedema conditions. Nonetheless, a proportion of survivors of cancer experience a burden of symptoms in their lower limbs that occur after cancer treatment.
Other limitations of this study include the possibly of volunteer bias in responding to the authors' mailed letter. It is plausible that the survivors of cancer who did not reply to the authors' survey were different from those who did reply. It is plausible that the survivors of cancer did not accurately report their symptoms, overestimating or underestimating the number of symptoms experienced. Some symptoms may be transient, and the participants may have only recalled the symptoms they experienced recently or at the time of completing the authors' survey or the symptoms that impaired physical function or quality-of-life to the greatest extent. The authors identified age, occupation, previous diagnosis of LLL, and number of self-reported symptoms as differences among the participants who volunteered to attend the in-person clinical assessment vs. those who did not volunteer. The authors anticipated inviting all participants for the in-person clinical assessment; this is why they limited their sampling framework to eligible survivors of cancer living in zip codes within a 10-mile radius around the University of Pennsylvania. It is plausible that the survivors of cancer living in this geographic region are different from other survivors of cancer for a variety of reasons (e.g., access to healthcare facilities, living conditions, etc.), limiting the generalizability of this study's findings. It is plausible that those who attended the in-person clinical assessment had greater awareness or concerns about their current symptoms compared with those who did not attend the in-person clinical assessment.
CONCLUSIONS
This study surveyed survivors of cancer who may be at increased risk for LLL based on primary tumor site and common treatments for those tumors. These data suggest that a large proportion of survivors of cancer are unaware of LLL and unaware of the signs and symptoms associated with LLL. This study's sample reported a variety of symptoms occurring after cancer treatment that may impair quality-of-life and physical functioning. There may be a subgroup of survivors of cancer who, although without LLL, report symptoms in their lower limbs. The likelihood that there is an underdiagnosis of LLL is supported by the empirical observation of identifying three previously undiagnosed cases, simply by offering an in-person clinical assessment.
In conclusion, those with a change in lower extremity symptoms should inform their healthcare provider for evaluation of possible LLL or other conditions amenable to medical and rehabilitative interventions. For those who are recently diagnosed with cancer, healthcare providers to strive to inform their patients of the likelihood of experiencing the
